Ocata Therapeutics Inc fka OCAT

[rocky301]

copper,

It seems to me that at that juncture -- when you have an approved treatment, we would need the support of a major pharma to get the treatment out on a scale commensurate with demand

NO doubt about that.

(recent PharmaTV Interview)
Gary Rabin:
"Well right now we obviously are deficit funding ourselves through our own capital, ultimately we enforce plan to commercialize this product probably in partnership with a large pharma or a biotech that has penetration into the ophthalmology surgeon market and the therapy that we are doing is the subretinal injection 50 to 200,000 RPE cells suspended in ceiling 150 micrometer of ceiling, so this is a very easily scalable, transportable model that looks very much like a traditional pharma product or a biologic."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62474597

(conference call)
I just returned from Europe where we had some great meetings. As far as the RPE program goes, it would be highly premature to seek partners early in the phase 1 study as we are hopeful that even though we are dealing with late stage patients, we will soon have data on retinal engraftment of our cells, and thier impact on photorecptor function. If we see no safety issues, and are able to detect some engraftment of our cells to the photoreceptor / Bruch's membrane, we will obviously be dealing from a much stronger valuation and negotiating position.